A Study of CT0596 in Plasma Cell Leukemia

NCT06988059 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Leukemia

Interventions

DRUG: CAR-T cells Infusion chimeric antigen receptor T cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]